NASDAQ:INFI

Infinity Pharmaceuticals News Headlines

$3.35
-0.10 (-2.90 %)
(As of 06/14/2021 10:39 AM ET)
Add
Compare
Today's Range
$3.32
$3.48
50-Day Range
$2.66
$3.47
52-Week Range
$0.78
$5.98
Volume14,992 shs
Average Volume2.81 million shs
Market Capitalization$296.97 million
P/E RatioN/A
Dividend YieldN/A
Beta2.28

Infinity Pharmaceuticals (NASDAQ INFI) News Headlines Today

SourceHeadline
-$0.13 Earnings Per Share Expected for Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) This Quarter-$0.13 Earnings Per Share Expected for Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) This Quarter
americanbankingnews.com - June 13 at 11:16 PM
Infinity Pharmaceuticals (NASDAQ:INFI) Share Price Passes Above 200-Day Moving Average of $0.00Infinity Pharmaceuticals (NASDAQ:INFI) Share Price Passes Above 200-Day Moving Average of $0.00
americanbankingnews.com - June 8 at 1:34 AM
Shareholders May Be More Conservative With Infinity Pharmaceuticals, Inc.s (NASDAQ:INFI) CEO Compensation For NowShareholders May Be More Conservative With Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) CEO Compensation For Now
finance.yahoo.com - June 3 at 12:57 PM
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Receives Average Rating of "Buy" from AnalystsInfinity Pharmaceuticals, Inc. (NASDAQ:INFI) Receives Average Rating of "Buy" from Analysts
americanbankingnews.com - May 29 at 5:30 AM
Short Interest in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Rises By 114.0%Short Interest in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Rises By 114.0%
americanbankingnews.com - May 28 at 5:50 PM
Were Not Very Worried About Infinity Pharmaceuticals (NASDAQ:INFI) Cash Burn RateWe're Not Very Worried About Infinity Pharmaceuticals' (NASDAQ:INFI) Cash Burn Rate
finance.yahoo.com - May 28 at 1:19 PM
Zacks: Analysts Anticipate Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Will Post Quarterly Sales of $460,000.00Zacks: Analysts Anticipate Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Will Post Quarterly Sales of $460,000.00
americanbankingnews.com - May 28 at 2:42 AM
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Expected to Post Earnings of -$0.13 Per ShareInfinity Pharmaceuticals, Inc. (NASDAQ:INFI) Expected to Post Earnings of -$0.13 Per Share
americanbankingnews.com - May 26 at 3:16 PM
Brokers Offer Predictions for Infinity Pharmaceuticals, Inc.s Q2 2021 Earnings (NASDAQ:INFI)Brokers Offer Predictions for Infinity Pharmaceuticals, Inc.'s Q2 2021 Earnings (NASDAQ:INFI)
americanbankingnews.com - May 21 at 7:00 AM
Brokers Issue Forecasts for Infinity Pharmaceuticals, Inc.s FY2024 Earnings (NASDAQ:INFI)Brokers Issue Forecasts for Infinity Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:INFI)
americanbankingnews.com - May 20 at 9:35 AM
Infinity Pharmaceuticals IncShs hosts conference call for investorsInfinity Pharmaceuticals IncShs hosts conference call for investors
markets.businessinsider.com - May 14 at 8:00 PM
BRIEF-Infinity Pharmaceuticals Reports Q1 2021 Financial Results And Provides Company UpdateBRIEF-Infinity Pharmaceuticals Reports Q1 2021 Financial Results And Provides Company Update
msn.com - May 14 at 9:47 AM
Infinity Pharmaceuticals: Q1 Earnings InsightsInfinity Pharmaceuticals: Q1 Earnings Insights
benzinga.com - May 14 at 9:47 AM
Infinity Announces the Date of Its First Quarter 2021 Financial Results Conference Call and WebcastInfinity Announces the Date of Its First Quarter 2021 Financial Results Conference Call and Webcast
finance.yahoo.com - May 6 at 11:45 AM
Infinity Pharmaceuticals (INFI) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseInfinity Pharmaceuticals (INFI) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
finance.yahoo.com - May 3 at 5:42 PM
Infinity to Present at the 7th Annual Truist Securities Life Sciences SummitInfinity to Present at the 7th Annual Truist Securities Life Sciences Summit
finance.yahoo.com - April 27 at 12:32 PM
FibroGen (FGEN) DMD Drug Pamrevlumab Gets FDAs Fast Track TagFibroGen (FGEN) DMD Drug Pamrevlumab Gets FDA's Fast Track Tag
finance.yahoo.com - April 13 at 12:00 PM
Infinity BiologiX (IBX) Announces Collaboration With Ginkgo Bioworks to Scale COVID Response Through Pooled Testing in K-12 SchoolsInfinity BiologiX (IBX) Announces Collaboration With Ginkgo Bioworks to Scale COVID Response Through Pooled Testing in K-12 Schools
businesswire.com - April 1 at 1:51 AM
If You Had Bought Infinity Pharmaceuticals (NASDAQ:INFI) Shares A Year Ago Youd Have Earned 285% ReturnsIf You Had Bought Infinity Pharmaceuticals (NASDAQ:INFI) Shares A Year Ago You'd Have Earned 285% Returns
finance.yahoo.com - March 29 at 1:51 PM
Is the Options Market Predicting a Spike in Infinity (INFI) Stock?Is the Options Market Predicting a Spike in Infinity (INFI) Stock?
finance.yahoo.com - March 19 at 10:04 AM
Infinity: Q4 Earnings SnapshotInfinity: Q4 Earnings Snapshot
finance.yahoo.com - March 16 at 7:13 PM
Infinity Pharmaceuticals: Q4 Earnings InsightsInfinity Pharmaceuticals: Q4 Earnings Insights
benzinga.com - March 16 at 7:13 PM
Infinity Pharmaceuticals earnings: heres what to expectInfinity Pharmaceuticals earnings: here's what to expect
markets.businessinsider.com - March 14 at 1:17 PM
Infinity to Present at the Oppenheimer & Co. Annual Healthcare ConferenceInfinity to Present at the Oppenheimer & Co. Annual Healthcare Conference
finance.yahoo.com - March 10 at 9:14 AM
Global Apoptosis Market Size 2021, Estimate CAGR Value, Growth Rate, Product Demand, Industry Share, Technology, Challenges and Restraints to 2026Global Apoptosis Market Size 2021, Estimate CAGR Value, Growth Rate, Product Demand, Industry Share, Technology, Challenges and Restraints to 2026
marketwatch.com - March 9 at 8:40 AM
Infinity to Present at the H.C. Wainwright Global Life Sciences ConferenceInfinity to Present at the H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - March 2 at 10:51 AM
Indolent Lymphoma Treatment Market 2021 by Growing Demands, Sales, Revenue, Gross Margin, Geographical Regions, and Forecast to 2027Indolent Lymphoma Treatment Market 2021 by Growing Demands, Sales, Revenue, Gross Margin, Geographical Regions, and Forecast to 2027
marketwatch.com - March 1 at 12:33 PM
Penny Stocks To Buy With Analysts Targeting 76%-209% UpsidePenny Stocks To Buy With Analysts Targeting 76%-209% Upside
marketwatch.com - February 26 at 3:29 PM
Piper Sandler initiates Infinity Pharmaceuticals at overweightPiper Sandler initiates Infinity Pharmaceuticals at overweight
seekingalpha.com - February 20 at 9:56 AM
Piper Sandler Initiates Coverage On Infinity Pharmaceuticals with Overweight Rating, Announces Price Target of $7Piper Sandler Initiates Coverage On Infinity Pharmaceuticals with Overweight Rating, Announces Price Target of $7
benzinga.com - February 18 at 5:01 PM
Infinity Announces Closing of $92 Million Public Offering of Common StockInfinity Announces Closing of $92 Million Public Offering of Common Stock
finance.yahoo.com - February 18 at 12:00 PM
Infinity Pharmaceuticals Announces Pricing Of $80M Public Offering Of 21M Shares Priced At $3.80/ShareInfinity Pharmaceuticals Announces Pricing Of $80M Public Offering Of 21M Shares Priced At $3.80/Share
benzinga.com - February 13 at 11:21 AM
Infinity Announces Pricing of $80 Million Public Offering of Common StockInfinity Announces Pricing of $80 Million Public Offering of Common Stock
finance.yahoo.com - February 12 at 12:39 PM
Infinity Announces Proposed Public Offering of Common StockInfinity Announces Proposed Public Offering of Common Stock
finance.yahoo.com - February 11 at 8:17 PM
Why Infinity Pharmaceuticals Is Skyrocketing TodayWhy Infinity Pharmaceuticals Is Skyrocketing Today
finance.yahoo.com - February 11 at 3:17 PM
Infinity Pharmaceuticals Announces Conference Call for the ASCO Genitourinary Cancers Symposium to Discuss Clinical Data fromInfinity Pharmaceuticals Announces Conference Call for the ASCO Genitourinary Cancers Symposium to Discuss Clinical Data from
bloomberg.com - February 11 at 10:17 AM
Infinity Pharmaceuticals Presents Data from Randomized, Placebo-Controlled, Phase 2 MARIO-275 Trial of Eganelisib and Nivolumab in Advanced Urothelial Cancer at ASCO Genitourinary Cancers SymposiumInfinity Pharmaceuticals Presents Data from Randomized, Placebo-Controlled, Phase 2 MARIO-275 Trial of Eganelisib and Nivolumab in Advanced Urothelial Cancer at ASCO Genitourinary Cancers Symposium
finance.yahoo.com - February 11 at 10:17 AM
Infinity Pharmaceuticals to Present at Upcoming BIO CEO & Investor ConferenceInfinity Pharmaceuticals to Present at Upcoming BIO CEO & Investor Conference
finance.yahoo.com - February 11 at 10:17 AM
Infinity Pharmaceuticals Announces Conference Call for the ASCO Genitourinary Cancers Symposium to Discuss Clinical Data from MARIO-275 Phase 2 StudyInfinity Pharmaceuticals Announces Conference Call for the ASCO Genitourinary Cancers Symposium to Discuss Clinical Data from MARIO-275 Phase 2 Study
finance.yahoo.com - February 10 at 6:12 PM
Pancreatic Cancer Market Research Report 2021 Covers Updated Data Considering Impact of Covid 19 on Share Size and Future DemandPancreatic Cancer Market Research Report 2021 Covers Updated Data Considering Impact of Covid 19 on Share Size and Future Demand
marketwatch.com - February 10 at 1:12 PM
F. Hoffmann-La Roche Ltd: Roche reports solid results in 2020F. Hoffmann-La Roche Ltd: Roche reports solid results in 2020
finanznachrichten.de - February 4 at 8:42 AM
Immunotherapy Using Immune-Checkpoint Inhibitors (ICI) Modulators Are Revolutionizing Oncology IndustryImmunotherapy Using Immune-Checkpoint Inhibitors (ICI) Modulators Are Revolutionizing Oncology Industry
finanznachrichten.de - January 25 at 12:18 PM
Heres Why Momentum Investors Will Love Infinity Pharmaceuticals (INFI)Here's Why Momentum Investors Will Love Infinity Pharmaceuticals (INFI)
finance.yahoo.com - January 20 at 5:22 PM
Infinity Pharmaceuticals to Participate in B. Riley Securities Virtual Oncology Investor ConferenceInfinity Pharmaceuticals to Participate in B. Riley Securities Virtual Oncology Investor Conference
finance.yahoo.com - January 15 at 7:50 PM
Infinity Pharmaceuticals Announces MARIO-275 Phase 2 Data in Patients with Advanced Urothelial Cancer to be Presented at ASCOInfinity Pharmaceuticals Announces MARIO-275 Phase 2 Data in Patients with Advanced Urothelial Cancer to be Presented at ASCO
bloomberg.com - January 11 at 9:08 PM
Infinity Pharmaceuticals Announces MARIO-275 Phase 2 Data in Patients with Advanced Urothelial Cancer to be Presented at ASCO Genitourinary Cancers SymposiumInfinity Pharmaceuticals Announces MARIO-275 Phase 2 Data in Patients with Advanced Urothelial Cancer to be Presented at ASCO Genitourinary Cancers Symposium
finance.yahoo.com - January 11 at 10:15 AM
Implied Volatility Surging for Infinity (INFI) Stock OptionsImplied Volatility Surging for Infinity (INFI) Stock Options
finance.yahoo.com - January 11 at 10:15 AM
Infinity Pharmaceuticals to Participate in Three Investor Conferences This MonthInfinity Pharmaceuticals to Participate in Three Investor Conferences This Month
finance.yahoo.com - January 7 at 11:53 AM
Infinity (INFI) Provides Data on Eganelisib in Urothelial CancerInfinity (INFI) Provides Data on Eganelisib in Urothelial Cancer
finance.yahoo.com - January 7 at 11:53 AM
Infinity Pharmaceuticals Provides Update for Eganelisib in Patients with Metastatic Urothelial CancerInfinity Pharmaceuticals Provides Update for Eganelisib in Patients with Metastatic Urothelial Cancer
finance.yahoo.com - January 6 at 3:22 PM
This page was last updated on 6/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.